Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Arthrodesis of the subtalar joint using a novel biphasic calcium phosphate bone graft
Study design: Retrospective level IV study
Background: Limited availability of autologous bone graft has led to a vast array of alternative bone graft options including allograft, demineralized bone matrices, cell-based matrices, and synthetic bone grafts. In this retrospective review, a control group of patients undergoing subtalar joint arthrodesis using a conventional bone graft was compared to a matched study group utilizing a novel synthetic biphasic calcium phosphate (BCP) bone graft with advanced surface topography.
Materials and methods: Seventeen consecutive patients underwent subtalar joint arthrodesis using a novel BCP with a unique submicron surface topography, either as a standalone graft or mixed with bone marrow aspirate. Fusion outcomes were assessed via radiographs at six-weeks and twelve-weeks. Clinical outcomes were assessed via weight bearing status at six-weeks and twelve-weeks. These results were compared to a matched study group of 15 patients undergoing subtalar joint arthrodesis using a conventional bone graft.
Results: Seventeen of seventeen (100%) of patients completed full follow up. Twelve of seventeen patients had complete fusion at 12 weeks (70%) and four of seventeen patients (23%) had partial fusion at 12 weeks. One of seventeen (5%) had revision arthrodesis. All patients were 100% weight bearing at 12 weeks. In the control group, ﬁfteen of ﬁfteen (100%) of patients completed full follow up. At 12 weeks, seven of ﬁfteen (46%) had complete fusion, seven of ﬁfteen (46%) had partial fusion, and one (6%) did not fuse and went on to revision surgery.
Conclusions: This novel submicron surface topography BCP offers a promising bone graft substitute for arthrodesis of the subtalar joint.
Citation: Fusco TA, Sage K, Rush S, Blom F, and Colvin K. et al. Arthrodesis of the subtalar joint using a novel biphasic calcium phosphate bone graft. Foot & Ankle Surgery: Techniques, Reports & Cases. 2022;2(1):100150.
Disclaimer: Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. Please refer to the Instructions for Use for a full list of indications, contraindications, precautions and warnings. For important safety and intended use information please visit kurosbio.com. MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.